Martha Arellano is a Hematology physician affiliated with Emory University. OpenAlex indexes 267 publications with 13,465 citations (h-index 46); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1365c Clifton Rd NE
Suite 1152 C
Atlanta, GA 303221013
Telephone
404-778-1900Registry record last updated 14 Dec 2010.
Clinical trials
- Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60
Sponsor: Emory University
- Omacetaxine for Consolidation and Maintenance
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- Blueprint Medicines CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.6%Kinase inhibitor39.2%Imatinib Mesylate37%Sprycel23%Iclusig16%Tasigna13%Bosulif10%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor12.5%Tibsovo100%Part D<11 patients+ 4 more classes in this area
Anti-infectives
20.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.5%Valacyclovir100%Part D≥15 patientsCephalosporin Antibacterial5.1%Cefpodoxime Proxetil100%Part D<11 patientsMusculoskeletal
6.1%Xanthine oxidase inhibitor6.1%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
New England Journal of Medicine
2024 - Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”